Incidence of amoxycillin-clavulanic acid associated hepatotoxicity in an Australian children's hospital
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
OBJECTIVES: Amoxycillin/clavulanic acid is the most common antimicrobial cause of drug-induced liver injury in adults. It is a less common cause of severe drug-related hepatotoxicity in children despite its frequent use. We studied the incidence, characteristics and predictive factors for amoxycillin/clavulanic acid hepatoxicity in children.
DESIGN: Retrospective cohort study of children who received oral or intravenous amoxycillin/clavulanic acid at a quaternary children's hospital over a 5-year period. Children were included if they had liver function tests (LFTs) determined at baseline, during and within 3 months after the treatment course. Causality was assessed using the Naranjo criteria for adverse drug reactions and Roussel Uclaf Causality Assessment Method.
RESULTS: Of 3271 children prescribed amoxycillin/clavulanic acid, 374 were included. Forty-nine (13%) had LFT abnormalities related to amoxycillin/clavulanic acid. Fourteen (3.6%) fulfilled Common Terminology Criteria for Adverse Events (CTCAE) grade 2 criteria with clinically significant hepatotoxicity. Age <2 years, sepsis, post-gastrointestinal surgical indications, prolonged treatment course of >7 days and higher cumulative amoxycillin (>10 g) and clavulanic acid dose (>1 g) were predictive of hepatotoxicity. The median time to resolution of LFT abnormalities was 4 weeks (range 3-7).
CONCLUSIONS: The incidence of amoxycillin/clavulanic acid related LFT abnormalities (CTCAE Grade 2 or above) in children was 3.6%. A prolonged treatment course >7 days, high cumulative amoxycillin (10 g) and clavulanic acid (>1 g) doses, those aged <2 years, and patients with sepsis or post-gastrointestinal surgery were predictive of a higher likelihood of abnormal LFTs. LFT monitoring should be considered in children receiving ≥7 days of treatment, particularly in those with other predisposing factors.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
---|---|
Enthalten in: |
The Journal of antimicrobial chemotherapy - 79(2024), 3 vom: 01. März, Seite 589-594 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Eldredge, Jessica A [VerfasserIn] |
---|
Links: |
---|
Themen: |
23521W1S24 |
---|
Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1093/jac/dkae009 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367872927 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367872927 | ||
003 | DE-627 | ||
005 | 20240304232404.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240201s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1093/jac/dkae009 |2 doi | |
028 | 5 | 2 | |a pubmed24n1316.xml |
035 | |a (DE-627)NLM367872927 | ||
035 | |a (NLM)38297994 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Eldredge, Jessica A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Incidence of amoxycillin-clavulanic acid associated hepatotoxicity in an Australian children's hospital |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.03.2024 | ||
500 | |a Date Revised 04.03.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
520 | |a OBJECTIVES: Amoxycillin/clavulanic acid is the most common antimicrobial cause of drug-induced liver injury in adults. It is a less common cause of severe drug-related hepatotoxicity in children despite its frequent use. We studied the incidence, characteristics and predictive factors for amoxycillin/clavulanic acid hepatoxicity in children | ||
520 | |a DESIGN: Retrospective cohort study of children who received oral or intravenous amoxycillin/clavulanic acid at a quaternary children's hospital over a 5-year period. Children were included if they had liver function tests (LFTs) determined at baseline, during and within 3 months after the treatment course. Causality was assessed using the Naranjo criteria for adverse drug reactions and Roussel Uclaf Causality Assessment Method | ||
520 | |a RESULTS: Of 3271 children prescribed amoxycillin/clavulanic acid, 374 were included. Forty-nine (13%) had LFT abnormalities related to amoxycillin/clavulanic acid. Fourteen (3.6%) fulfilled Common Terminology Criteria for Adverse Events (CTCAE) grade 2 criteria with clinically significant hepatotoxicity. Age <2 years, sepsis, post-gastrointestinal surgical indications, prolonged treatment course of >7 days and higher cumulative amoxycillin (>10 g) and clavulanic acid dose (>1 g) were predictive of hepatotoxicity. The median time to resolution of LFT abnormalities was 4 weeks (range 3-7) | ||
520 | |a CONCLUSIONS: The incidence of amoxycillin/clavulanic acid related LFT abnormalities (CTCAE Grade 2 or above) in children was 3.6%. A prolonged treatment course >7 days, high cumulative amoxycillin (10 g) and clavulanic acid (>1 g) doses, those aged <2 years, and patients with sepsis or post-gastrointestinal surgery were predictive of a higher likelihood of abnormal LFTs. LFT monitoring should be considered in children receiving ≥7 days of treatment, particularly in those with other predisposing factors | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Amoxicillin-Potassium Clavulanate Combination |2 NLM | |
650 | 7 | |a 74469-00-4 |2 NLM | |
650 | 7 | |a Clavulanic Acids |2 NLM | |
650 | 7 | |a Amoxicillin |2 NLM | |
650 | 7 | |a 804826J2HU |2 NLM | |
650 | 7 | |a Clavulanic Acid |2 NLM | |
650 | 7 | |a 23521W1S24 |2 NLM | |
700 | 1 | |a Pittet, Laure F |e verfasserin |4 aut | |
700 | 1 | |a Gwee, Amanda |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of antimicrobial chemotherapy |d 1981 |g 79(2024), 3 vom: 01. März, Seite 589-594 |w (DE-627)NLM000017701 |x 1460-2091 |7 nnns |
773 | 1 | 8 | |g volume:79 |g year:2024 |g number:3 |g day:01 |g month:03 |g pages:589-594 |
856 | 4 | 0 | |u http://dx.doi.org/10.1093/jac/dkae009 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 79 |j 2024 |e 3 |b 01 |c 03 |h 589-594 |